Deal Terminations Not The End Of The Road For Licensed Drugs
Executive Summary
Post-deal termination, approximately 14% of the drugs from those alliances go on to be approved, and of those still in development, nearly two-thirds advance at least one phase. Third in a series of follow-ups to IN VIVO’s 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.
You may also be interested in...
Up-Front Deal Economics May Not Match Drugs’ Likelihood Of Approval
In earlier development phases, most of the therapeutic classes with higher approval rates tend on average to have the larger up-front alliance payments. But in Phase III, licensees are paying top dollar for candidates in areas with the lowest likelihoods of approval.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
The Biopharma A List: Taking The Pulse Of Newco Creation
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.